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Background: Platelet-derived growth factor–BB (PDGF-BB) is highly expressed in the renal tissues of patients with
diabetic nephropathy, and it plays an important role in the initiation and progression of diabetic nephropathy. The
aim of this study was to evaluate the protective effects of root of Polygonum cuspidatum extract (PCE) on early
renal glomerular proliferation in streptozotocin (STZ)-induced diabetic rats.
Methods: PCE (100, 350 mg/kg/day) was administered to diabetic rats for 16 weeks. Blood glucose and albuminuria
were measured. Renal histology, α-smooth muscle actin (α-SMA), and proliferating cell nuclear antigen (PCNA)
expression levels were also examined.
Results: After 16 weeks of treatment with PCE, severe hyperglycemia and albuminuria were observed in the
diabetic rats. The expressions levels of α-SMA and PCNA proteins were significantly increased in the glomeruli of
the diabetic rats. The expression levels of PDGF-BB and its receptor expressions were greatly increased in the
glomeruli of the diabetic rats. However, PCE markedly reduced albuminuria in the diabetic rats. PCE inhibited
α-SMA and PCNA up-regulation and ameliorated PDGF-BB and PEGFR-ß protein expression in the diabetic rats. In
addition, the binding of PDGF-BB/PDGFR-ß was inhibited by PCE as shown by an in vitro assay.
Conclusions: These results suggest that PCE has an inhibitory effect on mesangial proliferation in diabetic renal
tissues via the inhibition of the interaction of PDGF-BB with its receptor. PCE may have beneficial effects in
preventing the progression of diabetic nephropathy.
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Diabetic nephropathy causes the majority of case of
end-stage renal disease, and it is an important cause of
increased mortality in patients with diabetes mellitus
(DM) worldwide. Platelet-derived growth factor (PDGF)
has been suggested to play a role in the pathophysiology* Correspondence: jskim@kiom.re.kr
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unless otherwise stated.of various fibroproliferative diseases, including pulmon-
ary fibrosis, systemic sclerosis, liver cirrhosis, cardiovas-
cular disease and kidney fibrosis [1,2]. The up-regulation
of the PDGF pathway has been shown in the kidneys of
diabetic animals and patients with DM [2-4]. PDGF po-
tently increases cell proliferation and matrix synthesis.
PDGF-BB, which is an isoform of PDGF that has been
the most closely linked with the development of various
renal diseases, is produced by glomerular mesangial cells
[5]. Moreover, PDGF-BB is highly expressed in diabetichis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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progression of diabetic nephropathy [6]. Hyperglycemia
has been is well characterized and albuminuria is consid-
ered to be one of the most sensitive markers of renal
injury, and albuminuria significantly increased within 6–8
weeks in the streptozotocin (STZ)-induced diabetic animal
model [7-10]. Moreover, the expression of the PDGF-B
chain or PDGFR-ß in mesangial cells is actually increased
in the glomeruli in this animal model [2].
Medicinal plants have been used as traditional remedies
for hundreds of years. Polygonum cuspidatum (P. cupida-
tum) is the dried root of Polygonum cuspidatum Sieb. et
Zucc. (Polygonaceae). It has been widely used as a medi-
cinal herb for a variety of purposes in Asian countries,
such as the treatment of inflammatory diseases, hepatitis,
tumors, and diarrhea [11]. This herb has also been used to
control oral disease in Korea [12]. In traditional Chinese
medicine, P. cuspidatum has been used for its anti-
diabetic, antibacterial properties [13-15]. Recently, it has
been reported that an herbal formulation containing of P.
cuspidatum prevented hepatic fibrosis by decreasing the
expression of transforming growth factor-beta (TGF-ß)
and α-smooth muscle actin (α-SMA) [16]. The general
understanding of the pathogenic factors leading to renal
fibrosis in diabetic nephropathy patients has considerably
expanded, and the mechanisms involving TGF-ß and
α-SMA have been found to be important to the develop-
ment of diabetic renal fibrosis [17-19]. Therefore, in this
study, we investigated the protective effect of an ethanol
extract of P. cuspidatum (PCE) against renal injury and
fibrosis in STZ-induced diabetic rats.
Methods
Preparation of Polygonum cuspidatium extract (PCE)
Root of Polygonum cuspidatum was purchased from a
commercial supplier in Jung-dong, Daejeon, Korea, in
November 2008 and identified by Prof. Ju Han Kim at
the Department of Life Sciences, Gachon University. A
voucher specimen was deposited at the Herbarium of the
Diabetic Complication Research Team, Korea Institute of
Oriental Medicine (KIOM). The dried and ground plant
material (6.8 kg) was extracted with ethanol (3 × 36 L) by
maceration at room temperature for 3 days, and the ex-
tracts were combined and concentrated in vacuo at 40°C
to create lyophilized PCE (580 g).
Animals and induction of diabetes
The experiments were performed in accordance with the
National Institutes of Health (NIH) Guide for the Care
and Use of Laboratory Animals and approved by the
Korea Institute of Oriental Medicine Institutional Animal
Care and Use Committee. In our study, six-week-old male
SD rats purchased from the Charles River Laboratory
(Waltham, MA, USA) were acclimated for 1 week prior tothe study. Our study was initiated using 8-week-old male
SD rats (weighting, ~200 g), which were monitored for
16 weeks. Diabetes was induced in the rats by a single
injection of streptozotocin (STZ, 60 mg/kg, i.p.). Age-
matched control rats received an equal volume of vehicle
(0.01 M citrate buffer, pH 4.5). Two days after the injec-
tion, a blood sample was collected from the ratil vein to
measure the blood glucose level. Rats with a blood glucose
level over 300 mg/dl were considered diabetic rats. At
8 weeks of age, the rats were randomly assigned to one of
four groups (n = 8). PCE was dissolved in vehicle (0.5% w/
v carboxyl methylcellulose solution) to a concentration of
50 mg/ml. Two groups of STZ-induced diabetic rats
received daily gastric gavage of PCE (100 and 350 mg/kg),
and the other groups were administered the same amount
of vehicle gavage for 16 weeks. Blood glucose levels and
body weight were monitored consecutively.
Metabolic and morphological analyses
After 16 weeks of treatment, blood glucose was mea-
sured using an automated analyzer (Hitachi, Tokyo,
Japan). Blood samples were collected from the tail vein
after a 16-h fast. Individual rats were placed in metabolic
cages to obtain 24-h urine collections, and urinary albu-
min excretion levels were measured using a sandwich
enzyme-linked immunosorbent ELISA assay kit accord-
ing to the manufacturer’s manual (Life Diagnostics, Inc.,
PA, USA). Rat albumin present in the urine sample was
captured by an anti-rat albumin antibody that had been
pre-adsorbed on the surfaces of microtiter wells. After
sample binding, unbound proteins and molecules were
washed off with washing buffer, and a biotinylated detec-
tion antibody was added to the wells to bind to the
captured albumin. Strepavidin-conjugated horseradish
peroxidase (SA-HRP) was then added to catalyze a col-
orimetric reaction with the chromogenic substrate
3,3′,5,5′-tetramethylbenzidine(TMB). This colorimetric
reaction produces a blue product, which turns yellow
when the reaction is terminated by the addition of stop
solution (0.1 M H2SO4). The resulting, yellow reaction
products were read at 450 nm using a microtiter plate
reader (Bio-Tek, Winooski, VT, USA). Renal cortexes
were fixed in 10% formaldehyde and embedded in paraf-
fin, and 4-μm-thick sections were prepared. The sections
were stained with periodic acid-Schiff (PAS) reagent and
hematoxylin as a counterstain.
Western blot analysis
The renal cortex was lysed with RIPA buffer (pH 7.5)
(Pierce, IL, USA). Western blot analysis was performed
as previously described [20]. Equal amounts (30 μg) of
protein were separated by electrophoresis on SDS-
polyacrylamide gels, electroblotted on polyvinylidene
fluoride (PVDF) membranes and probed using primary
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USA). The immunoblots were developed using an en-
hanced chemiluminescence detection system (Amersham
Bioscience, NJ, USA) with HRP-conjugated secondary
antibodies. Protein expression levels were determined by
analyzing the signals captured on the PVDF membranes
using an image analyzer (Las-3000, Fuji Photo, Tokyo,
Japan).
Immunohistochemical and immunofluorescent staining
Renal cortexes were fixed in 10% formaldehyde and em-
bedded in paraffin, and 4-μm-thick sections were prepared.
Staining was performed as previously described [15]. The
antibodies used included rabbit anti-proliferating cell
nuclear antigen (PCNA, Santa Cruz, CA, USA), mouse
anti-PDGF-BB (R&D Systems, MN, USA), mouse anti-
PDGFR-ß (R&D Systems), rabbit anti-α-SMA (Santa Cruz,
CA, USA) and mouse anti-thy 1.1 (a mesangial cell marker;
Millipore, MA, USA). For the detection of PDGF-BB and
PDGFR-ß, the sections were incubated using an Envision
kit (DAKO, CA, USA) and visualized by 3,3′-diaminoben-
zidine tetrahydrochloride (DAB). To detect PCNA and
α-SMA, the sections were incubated with Texas red-
conjugated goat anti-rabbit IgG (Santa Cruz, CA, USA)
and fluorescein isothiocyanate-conjugated goat anti-rabbit
IgG (Santa Cruz, CA, USA), respectively, and detected by
fluorescence microscopy (Olympus, Tokyo, Japan). To
characterize the proliferation of the mesangial cells, we
performed double staining for PCNA and Thy 1.1. using
the same section. To prevent cross-reactions between the
two labeling procedures, the slides were incubated with
normal mouse serum (Dako, CA, USA). To detect PCNA
and Thy 1.1, the sections were incubated with fluorescein
isothiocyanate-conjugated goat anti-rabbit IgG (Santa
Cruz, CA, USA) and Texas red-conjugated goat anti-
mouse IgG (Santa Cruz, CA, USA), respectively. Negative
controls for immunohistochemistry were prepared by incu-
bating the sections with nonimmune serum instead of
primary antibody. For morphometric analysis, the number
of positive cells or positive signal areas per one glomerulus
in a total of 50 glomeruli was determined using ImageJ
software (NIH, Bethesda, MD, USA).
In vitro assay for ligand receptor binding inhibition
To investigate the inhibitory effect of PCE on PDGF-BB/
PDGFR-ß ligand receptor binding, ligand binding was
examined by a sandwich ELISA assay in vitro. A total of
50 μl of a 0.05 μg dose of recombinant human PDGF-BB
(R&D Systems, MN, USA) was pre-coated and incubated
on a microplate for 24-h at 4°C and was then washed
with PBS (pH 7.4). Next, the sample was blocked with
100 μl of CAS block solution (Life Technologies, CA,
USA) for 30 min at 37°C and then washed with PBS.
The sample was then added to 50 μl recombinanthuman (rh) PDGFR-ß /FC chimera labeled with peroxid-
ase (Dojindo, Kumanoto, Japan) and 50 μl of a serial
dilution of the PCE mixture in a microplate pre-coated
with rh PDGF-BB. The samples were incubated for 1 h
at 37°C and then washed with PBS. A TMB chromogen
solution was used as a substrate for the horseradish
peroxidase. After the reaction was terminated with stop
buffer (0.1 M H2SO4), and a yellow reaction product
formed, its absorbance was measured at 450 nm using a
microtiter plate reader (Bio-Tek, Winooski, VT, USA).
The inhibition of PDGF-BB ligand receptor binding was
expressed as the percentage decrease in optical density
(OD 450 nm). We calculated the IC50 concentration
(ug/ml) as the 50% inhibition of PDGF-BB/ PDGFR-ß
ligand binding.
Statistical analysis
The data are expressed as the mean ± SEM and were
analyzed by one-way analysis of variance (ANOVA),
followed by Tukey’s multiple comparison test or by an
unpaired Student’s t-test using GraphPad Prism 5.0
software (GraphPad, San Diego, CA, USA). Differences
of P < 0.01 were considered statistically significant.
Results
Body weights and metabolic parameters
At 16 weeks of treatment, the body weights were signifi-
cantly decreased in the vehicle-treated diabetic rats com-
pared with the normal control rats. However, there was
no difference in body weight between the vehicle-treated
diabetic rats and PCE-treated diabetic rats. The blood
glucose levels increased by approximately 3-fold in the
vehicle-treated diabetic rats compared with normal con-
trol rats (P < 0.01). There was no statistically significant
difference between the vehicle-treated diabetic rats and
PCE-treated diabetic rats with respect to blood glucose
levels (Table 1). These resulting data demonstrated that
PCE maybe has independent effect on glucose-lowering
and body weight.
Morphology and urinary albumin levels
Mesangial matrix expansion is considered a hallmark of
diabetic nephropathy [21]. At 24 weeks of age, vehicle-
treated diabetic rats showed focal mesangial matrix expan-
sion, and albuminuria was significantly increased in the
vehicle-treated diabetic rats compared to the normal con-
trol rats (Figure 1A). However, PCE treatment ameliorated
the mesangial expansion and albuminuria compared with
the vehicle-treated diabetic rats (Figure 1A and B).
PDGF expression in renal glomeruli
To investigate the effect of PCE on expression of PDGF
and its receptor in diabetic renal injury, immunohisto-
chemistry and western blotting analysis were performed.
Table 1 Metabolic and physical parameters
NOR DM PCE-100 PCE-350
Blood glucose (mg/dl) 162.1 ± 11.0 587.3 ± 43.5* 530.3 ± 58.1 474.2 ± 88.4
Body weight (g) 475.9 ± 10.7 208.5 ± 12.1* 205.5 ± 23.1 206.0 ± 16.4
NOR, normal rat; DM, STZ-induced diabetic rat; PCE-100, DM treated with PCE (100 mg/kg); PCE-350, DM treated with PCE (350 mg/kg). All data are expressed as
the mean ± SEM (n=8). *P <0.01 vs. NOR group.
Sohn et al. BMC Complementary and Alternative Medicine 2014, 14:477 Page 4 of 9
http://www.biomedcentral.com/1472-6882/14/477Immunohistochemical staining of PDGF-BB and PDGFR-
ß in the glomeruli were mainly localized to the glomerular
mesangial cells revealing a significant increase in the
vehicle-treated diabetic rats compared with the normal
control rats. This increase of PDGF-BB and PDGFR-ß
expression in the glomeruli in the vehicle-treated diabetic
rat was attenuated by PCE treatment (Figure 2A and B).
Western blot analysis showed that, PDGF-BB and its
receptor in the renal cortex were also markedly increased
in the vehicle-treated diabetic rats compared with the nor-
mal control rats. PCE reduced these diabetes-induced
increases in PDGF-BB and PDGFR-ß expressions in a
dose-dependent manner (Figure 2C and D). This result
demonstrated that PCE prevents renal mesangial prolifera-
tion in diabetic nephropathy.
Inhibition of PDGF-BB ligand receptor binding assay
To investigate whether PCE could inhibit the binding of
the PDGF ligand to its receptor, a sandwich ELISA assay
was performed. PCE showed inhibition effect on binding
of the PDGF ligand to its receptor in a concentration-
dependent manner. PCE exhibited an inhibitory effect
on the binding of the PDGF-BB ligand to its receptor
(IC50 = 0.185 ± 0.14 μg/ml) (Figure 3).Figure 1 Renal histopathology and albuminuria. (A) Periodic acid-Schif
experimental group. NOR, normal rat; DM, STZ-induced diabetic rat; PCE-10
(350 mg/kg). All data are expressed as the mean ± SEM (n=8). *P <0.01 vs.Expression of α-SMA and PCNA in renal glomeruli
Mesangial proliferation is considered a prominent fea-
ture of diabetic nephropathy. The expression level of
proliferation markers, such as α-SMA and PCNA, were
measured using immunohistochemistry and western blot
analysis. Immunohistochemical staining of α-SMA and
PCNA was markedly more visible in the diabetic renal
glomeruli compared with normal glomeruli. PCE treat-
ment showed decreased expression of α-SMA and
PCNA in the diabetic glomeruli (Figure 4A and B). The
western blot assay indicated that, the expressions levels
of α-SMA and PCNA were significantly increased in the
vehicle-treated diabetic rats compared with the normal
control rats. The high-dose PCE treatment markedly
reduced these diabetes-induced increases in α-SMA and
PCNA expression (Figure 4C and D). In addition, to
investigate whether the enhanced protein expression was
colocalized to the mesangial cells of the glomeruli,
PCNA and Thy 1.1, which is a mesangial cell marker
[22], were visualized by double immunofluorescence
staining. Thy 1.1 was positively stained in the glomerular
mesangial cells for all of the experimental rats. PCNA
expression was significantly increased in the vehicle-
treated diabetic rats compared with the normal controlf staining of glomeruli. 400× magnification. (B) Albuminuria in the
0, DM treated with PCE (100 mg/kg); PCE-350, DM treated with PCE
NOR group, # P <0.01 vs. DM group, and +P <0.01 vs. PCE-100 group.
Figure 2 Effects of PCE on PDGF-BB and PDGFR-ß in the renal glomeruli. (A) Immunohistochemical staining of PDGF-BB and (B) PDGFR-ß.
400× magnification. Morphometric analysis of western blots showing (C) PDGF-BB and (D) PDGFR-ß expression in the renal cortex for each group.
All data are expressed as the mean ± SEM (n=8). *P <0.01 vs. NOR group; #P <0.01 vs. DM group, and +P <0.01 vs. PCE-100 group.
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localized to a region of Thy 1.1-positive mesangial cells
in the diabetic renal tissue (Figure 5). However, the
high-dose PCE treatment significantly decreased PCNA
expression in the diabetic rats (Figure 5).Figure 3 Inhibitory effects of PCE on the binding of the PDGF-
BB ligand with its receptor in vitro. The experiments were
performed in triplicate. All data are expressed as the mean ± SEM.Discussion
Our current study demonstrated that PCE treatment sig-
nificantly improved albuminuria, which is a biochemical
marker of renal function in diabetic rats. In addition,
PCE prevented mesangial expansion and proliferation in
these diabetic rats. Of particular interest, our study
showed that PCE exhibits inhibitory activity against the
binding of the PDGF-BB ligand to its receptor, PDGFR-
ß. Moreover, PCE reduced the expression of α-SMA and
PCNA in the diabetic rats.
Hyperglycemia and albuminuria are present in STZ-
induced diabetic rats, and diabetic nephropathy progresses
rapidly in this animal model [23]. Hyperglycemia leads to
the destruction of the glomerular filtration barrier, leading
to glomerular damage and resulting in urinary protein or
albumin leakage, exacerbating the progression of diabetic
nephropathy [24,25]. Albuminuria is the main pathologic
feature of many primary glomerular diseases including
diabetic nephropathy [7]. Consistent with this interpret-
ation, our study demonstrated that albuminuria and focal
Figure 4 Effect of PCE on α-SMA and PCNA expression in the renal glomeruli. (A) Immunofluorescence staining for α-SMA and (B) PCNA
400× magnification. Western blot analysis of (C) α-SMA and (D) PCNA expression in the renal cortex for each group. All data are expressed as the
mean ± SEM (n=8). *P <0.01 vs. NOR group; #P <0.01 vs. DM group, and +P <0.01 vs. PCE-100 group.
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in the vehicle-treated diabetic rats. However, our study
showed that PCE treatment ameliorated the enhanced
diabetes-induced renal dysfunction, such as albuminuria
glomerular matrix expansion. Although P. cuspidatum has
anti-diabetic property [13], our data shows that PCE
inactived on blood glucose and body weight in diabetic
induced rat. However, various anti-diabetic drugs, such as
metformin, dipeptidyl peptidase 4 (DPP4) inhibitors, al-
though it has been successfully work to blood glucose low-
ering in type 2 diabetes, have been repurposed from other
clinical indications to treat renal injury. Actually, Kanasaki
et al. and Liu et al. investigated the anti-fibrotic effect of
linagliptin, DPP4 inhibitor, in type 1 model of diabetic
nephropathy [26,27]. These studies demonstrate that an
insulin-deficient model of diabetes enable the evaluation
of the effects of the DPP4 inhibitor independent of gly-
cemic control and body weight. Also, these studies provide
information regarding renal benefit of DPP4 inhibitor inde-
pendent of glycemic control and body weight. Moreover,metformin, a well-known anti-diabetic drug for type 2 dia-
betes mellitus (T2DM), had no effect on body weight and
blood glucose in type 1 diabetes mellitus (T1DM) [28,29].
However, our study demonstrated that PCE has effect
on the reno-protective action. Therefore, PCE possibly
has reno-protective effect independent body weight and
hypoglycemic effect.
In this study, we also found that the treatment of dia-
betic rats with PCE ameliorated mesangial expansion by
inhibiting the binding activity of PDGF-BB to its receptor,
PDGFR-ß. Mesangial expansion is one of the major patho-
logic factors of diabetic nephropathy. The proliferation of
mesangial cells is a prominent feature of glomerular
diseases, including diabetic nephropathy [30]. PDGF has
been consistently implicated in the cell proliferation and
extracellular matrix (ECM) accumulation that character-
izes progressive glomerular diseases [30,31]. PDGF-BB is
one of the classical isoforms of PDGF, which consists of
two PDGF-B chains linked by a disulfide bond. Moreover,
PDGF-BB has been demonstrated to play important roles
Figure 5 Effect of PCE on mesangial cell proliferation in the renal glomeruli. Immunofluorescence staining was performed with anti-thy 1.1,
which is a specific marker for mesangial cells, and anti-PCNA antibody and visualized with Texas-red and fluorescein isothiocyanate (FITC),
respectively, using a fluorescence microscope. Representative merged micrographs (yellow) of four independent experiments are shown at
400× magnification.
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[32]. PDGF-BB has received considerable attention as the
major mediator of mesangial cell proliferation, promoting
the up-regulation of PDGF and its receptor in mesangial
cells [5,33]. In the early stages of diabetic nephropathy,
mesangial cells express high levels of PDGF-BB, which
binds to PDGFR-ß, resulting in an increase glomerular
volume, inducing the proliferation and overgrowth of
mesangial cells [5]. The up-regulation of PDGF-BB and its
receptor in the mesangial cells of diabetic rats may be re-
sponsible for the proliferation of these cells and the accu-
mulation of ECM proteins in the mesangium as observed
in the early stages of diabetes [2,34]. In addition, ECM
proteins, such as α-SMA and PCNA, have been regarded
as appropriate indicators of mesangial proliferative glom-
erulonephritis, including diabetic nephropathy [35,36].
P. cuspidatum has been broadly utilized as a medicinal
herb in Asian countries, including Korea. In our study,
PCE exhibited inhibitory activity on the binding of the
PDGF-BB ligand to its receptor, PDGFR-ß, showing anIC50 value of 0.185±0.14 μg/ml. We also performed a
dot blot assay to determine the affinity of PCE for
PDGF-BB or PDGFR-ß (see Additional file 1). This assay
showed that PCE did not directly bind to PDGF-BB or
PDGFR-ß, indicating its lack of selective affinity. Resver-
atrol and emodin, which are major components of the
activated form of PCE, are phenolic compounds that are
concentrated in P. cuspidatum and have been studied
for their anti-diabetic effects in vitro [37,38]. An ethanolic
extract of P. cuspidatum has been demonstrated to exhibit
comprehensive and suppressive effects on inflammatory
and oxidative stresses [39] and significantly enhance the
rate of wound healing in rats and humans [40,41]. In our
previous study, an extract of P. cuspidatum radix has been
shown to exhibit strong anti-lipase activity [42]. Resvera-
trol is a natural anti-oxidant polyphenol that is present in
P. cuspidatum and has received increased attention in re-
cent years. This strong polyphenolic compound has been
shown to have several biological functions, including anti-
inflammatory and antioxidant activities [43]. Additionally,
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TGF- ß1 and fibronectin expression in cultured mesangial
cells [44]. In our study, PCE showed potential for prevent-
ing mesangial proliferation and ECM overgrowth in the
diabetic kidney due to its inhibitory effects on PDGF-BB/
PDGFR-ß binding. Although the major chemical com-
pounds of PCE include resveratrol and emodin, we did not
assess the combined effect of these compounds on diabetic
nephropathy. However, a previous study has demonstrated
that resveratrol or/and emodin ameliorates renal function
in diabetic rodents and suppresses high glucose-induced
glomerular mesangial cell proliferation by inhibiting the
NF-kB pathway [44-47]. Based on previous reports and our
in vivo results, the ability of PCE to protect against renal
damage may be due to the effect of these compounds.
Conclusions
In conclusion, renal mesangial expansion and albumin-
uria in diabetic rats were ameliorated by treatment with
PCE. PCE exerts anti-proliferative effects via inhibition
of the PDGF-BB/PDGFR-ß signaling pathway in diabetic
renal glomeruli. Therefore, our study indicates that ther-
apies targeting mesangial proliferation may be signifi-
cantly beneficial to patients with diabetic nephropathy
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